Ono Pharmaceutical Co., Ltd.
OPHLY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | – | – | – | – |
| - Cash | – | – | – | – |
| + Debt | – | – | – | – |
| Enterprise Value | – | – | – | – |
| Revenue | $487 | $503 | $447 | $361 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Gross Profit | $339 | $376 | $337 | $268 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| EBITDA | $92 | $178 | $162 | $124 |
| % Margin | 18.8% | 35.5% | 36.2% | 34.2% |
| Net Income | $50 | $128 | $113 | $81 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS Diluted | 35.47 | 88.87 | 76.92 | 54.05 |
| % Growth | -60.1% | 15.5% | 42.3% | – |
| Operating Cash Flow | – | – | – | – |
| Capital Expenditures | – | – | – | – |
| Free Cash Flow | – | – | – | – |